SEC Form 4 · accession 0001209191-16-111459

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Mar 30, 2016

Accepted (ET)

Apr 1, 2016 · 4:03 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Mar 30, 2016	M	5,130	$35.35	A	270,414	D
Common Stock^F2,F3	Mar 30, 2016	S	3,310	$78.31	D	267,104	D
Common Stock^F2,F4	Mar 30, 2016	S	820	$78.90	D	266,284	D
Common Stock^F2,F5	Mar 30, 2016	S	600	$80.08	D	265,684	D
Common Stock^F2,F6	Mar 30, 2016	S	400	$81.07	D	265,284	D
Common Stock	holding	—	—		—	13,286	I	401k
Common Stock	holding	—	—		—	122,700	I	Common Stock Held In Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7	$35.35	Mar 30, 2016	M	5,130	D	—	Jul 19, 2016	Common Stock	5,130	71,830	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $78.31 (range $77.69 to $78.66).
F4Open market sales reported on this line occurred at a weighted average price of $78.90 (range $78.69 to $79.20).
F5Open market sales reported on this line occurred at a weighted average price of $80.08 (range $79.83 to $80.38).
F6Open market sales reported on this line occurred at a weighted average price of $81.07 (range $81.00 to $81.13).
F7Fully vested.